This trial investigates transdermal patches of rivastigmine (a cholinesterase inhibitor) compared to a placebo to identify if rivastigmine can prevent falls in Parkinson’s disease.
To be eligible, the participants enrolled must:
- have had at least 1 fall in the last 12 months
- have a diagnosis of idiopathic Parkinson’s (Hoehn & Yahr stage 1-4)
- not have a diagnosis of dementia
The participants receive rivastigmine or placebo matched transdermal patches from the clinical trial pharmacy in the participating NHS trust.
They are started at a dose strength of 4.6mg/24h and uptitrated after 1 month to 9.5mg/24h and again after 5 months to 13.3mg/24h.
Continuation of the study medication after the trial is at the discretion of the treating physician as rivastigmine patches are not currently licensed for use in Parkinson’s disease.
If you would like more information, or to request a copy of the SmpC (RSI for the trial), please contact firstname.lastname@example.org or call 0117 428 3111.